Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11926825 Compounds and methods for reducing ATXN2 expression

Patent 11926825 was granted and assigned to Ionis Pharmaceuticals on March, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

All edits

Edits on 14 Mar, 2024
"Created via: Patent importer"
Golden AI profile picture
Golden AI
created this topic on 14 Mar, 2024
Edits made to:
Infobox (+64 properties)
Article (+595 characters)
‌

 US Patent 11926825 Compounds and methods for reducing ATXN2 expression

Article

Patent abstract

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN2 RNA in a cell or animal, and in certain instances reducing the amount of Ataxin-2 protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.

Infobox
Is a
Patent
Patent
0
Patent Applicant
Ionis Pharmaceuticals
Ionis Pharmaceuticals
0
Current Assignee
Ionis Pharmaceuticals
Ionis Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
119268250
Patent Inventor Names
Frank Rigo0
Susan M. Freier0
Date of Patent
March 12, 2024
0
Patent Application Number
172388140
Date Filed
April 23, 2021
0
Patent Citations
‌
US Patent 11111494 Compositions for modulating Ataxin 2 expression
0
‌
US Patent 11078486 Compounds and methods for reducing ATXN2 expression
0
‌
US Patent 7101993 Oligonucleotides containing 2′-O-modified purines
0
‌
US Patent 7262177 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
0
‌
US Patent 7374927 Methods of analysis of degraded nucleic acid samples
0
‌
US Patent 7399845 6-modified bicyclic nucleic acid analogs
0
‌
US Patent 7427672 Artificial nucleic acids of n-o bond crosslinkage type
0
‌
US Patent 7491805 Conjugates and compositions for cellular delivery
0
‌
US Patent 7547684 5′-modified bicyclic nucleic acid analogs
0
‌
US Patent 7569686 Compounds and methods for synthesis of bicyclic nucleic acid analogs
0
‌
US Patent 7572582 Oligonucleotide analogues
0
‌
US Patent 7666854 Bis-modified bicyclic nucleic acid analogs
0
‌
US Patent 7696345 Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
0
‌
US Patent 7723509 IRNA agents with biocleavable tethers
0
‌
US Patent 7741457 6-modified bicyclic nucleic acid analogs
0
‌
US Patent 7750131 5′-modified bicyclic nucleic acid analogs
0
‌
US Patent 7875733 Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
0
‌
US Patent 7888497 Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
0
‌
US Patent 7939677 Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
0
‌
US Patent 8022193 6-modified bicyclic nucleic acid analogs
0
‌
US Patent 8030467 5′-modified bicyclic nucleic acid analogs
0
‌
US Patent 8034909 Oligonucleotide analogues
0
‌
US Patent 8080644 Oligonucleotide analogues
0
‌
US Patent 8088746 Bis-modified bicyclic nucleic acid analogs
0
‌
US Patent 8088904 Tetrahydropyran nucleic acid analogs
0
‌
US Patent 8106022 Carbohydrate conjugates as delivery agents for oligonucleotides
0
‌
US Patent 8124745 Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
0
‌
US Patent 8153365 Oligonucleotide analogues
0
‌
US Patent 8268980 5′-modified bicyclic nucleic acid analogs
0
‌
US Patent 8278283 6-disubstituted or unsaturated bicyclic nucleic acid analogs
0
‌
US Patent 8278425 None
0
‌
US Patent 8278426 Carbocyclic bicyclic nucleic acid analogs
0
‌
US Patent 8440803 Tetrahydropyran nucleic acid analogs
0
‌
US Patent 8501805 Substituted alpha-L-bicyclic nucleosides
0
‌
US Patent 8530640 Bicyclic cyclohexitol nucleic acid analogs
0
‌
US Patent 8546556 Carbocyclic alpha-L-bicyclic nucleic acid analogs
0
‌
US Patent RE44779 Bicyclonucleoside and oligonucleotide analogues
0
‌
US Patent 8728736 Methods and compositions for multiplex PCR
0
‌
US Patent 8796437 Tetrahydropyran nucleic acid analogs
0
‌
US Patent 8828956 Carbohydrate conjugates as delivery agents for oligonucleotides
0
‌
US Patent 9005906 Tetrahydropyran nucleic acid analogs
0
‌
US Patent 9012421 Bicyclic cyclohexose nucleic acid analogs
0
‌
US Patent 9127276 Conjugated antisense compounds and their use
0
‌
US Patent 9290760 Modified iRNA agents
0
‌
US Patent 10006027 Methods for modulating Ataxin 2 expression
0
‌
US Patent 10308934 Compositions for modulating Ataxin 2 expression
0
‌
US Patent 10533178 Methods for modulating Ataxin 2 expression
0
‌
US Patent 6844431 Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto
0
‌
US Patent 7015315 Gapped oligonucleotides
0
‌
US Patent 7034133 Oligonucleotide analogues
0
‌
US Patent 7053207 L-ribo-LNA analogues
0
Patent Primary Examiner
‌
Brian Whiteman
0
CPC Code
‌
C12N 2310/14
0
‌
C12N 15/113
0

Find more entities like US Patent 11926825 Compounds and methods for reducing ATXN2 expression

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.